OREX Key Stats
- The 9 Most Obese Countries in the World Fool 2:05 PM
- Orexigen Therapeutics to Present at the UBS Global Healthcare Conference PR Newswire May 17
- Due Diligence in Finding the Value of Pharmaceuticals: Expert Portfolio Manager ... May 16
- Orexigen Therapeutics' Management Presents at Bank of America Merrill Lynch Heal... May 15
- Weight Loss Isn't Just for Looking Good Anymore Fool May 15
- Will Obesity Drugs Gain Soon? May 15
- Will Obesity Drugs Gain Soon? Fool May 14
- Looking at Arena Following Sell-Off May 14
- Vivus Starting To Gain The Advantage Over Arena May 14
- Nasdaq stocks posting largest percentage decreases May 13
OREX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Orexigen Therapeutics is up 75.29% over the last year vs S&P 500 Total Return up 31.64%, Vivus down 42.05%, and Arena Pharmaceuticals up 44.29%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for OREX
Pro Report PDF for OREX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download OREX Pro Report PDF
Pro Strategies Featuring OREX
Did Orexigen Therapeutics make it into our Pro Portfolio Strategies?